Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent quarters. The company markets Linzess in the United States in collaboration with ...

Ironwood Pharmaceuticals IRWD reported adjusted earnings of 24 cents per share for the third quarter of 2025, which comprehensively beat the Zacks Consensus Estimate of 9 cents. The company had ...

Ironwood Pharma ( ($IRWD) ) has shared an announcement. On November 25, 2025, the U.S. Department of Health and Human Services announced the ...

U.S. Medicare price cuts of up to 85% will have a lesser impact on drugmakers than initially feared, with most of the hit ...

The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on 15 costly prescription drugs under ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of the program’s price negotiations, touting a total of $12 billion saved ...

When life gets hectic, nutrition often falls by the wayside. While one off-schedule week isn’t necessarily harmful to your ...

This approval is notable as Linzess becomes the first treatment approved for IBS-C in pediatric patients, having previously been approved for adult patients. In another development, Ironwood ...

The low FODMAP diet has clear benefits for IBS, but all-too-common eating disorders can be important deal-breakers, experts underscore in ACG debate.